StreetAlpha.app
Home › Stocks › ICLR

Icon PLC (ICLR)

Healthcare
$186.71
▼ −1.92%
LAST CLOSE · NOV 20

ICON provides outsourced clinical development and commercialization services to pharmaceutical, biotech and medical device companies. It last closed at $186.71 on Nov 20, down 1.92% on the day. Over the last 12 months ICLR insiders bought $0 of stock on the open market and sold $8.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is ICLR in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ICLR.

Key Stats

Last 12 months
Results
Revenue
$8.2B
+1.8% vs a year ago
Net income
$448.7M
+55.9% vs a year ago
Free cash flow
$857.1M
10.4% margin
Operating margin
8.7%
$718.3M operating income
Balance sheet
Cash & equivalents
$809.0M
At Sep 30
Debt
$3.4B
At Sep 30
Shareholder equity
$9.1B
Buybacks
$400.0M
Last 12 months
Employees40,100 (Dec 31, 2025)
ExchangeNasdaq
Financials history
FY2021: $5.5B$5.5BFY2021FY2022: $7.7B$7.7BFY2022FY2023: $8.1B$8.1BFY2023FY2024: $8.2B$8.2BFY2024FY2025: $8.3B$8.3BFY2025

From ICLR's SEC filings, latest 20-F for the period ending Sep 30, 2026 (filed May 27). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.

Next report
—
No date on file yet
Reported EPS
—
Quarter ended Sep 2026
Year ago EPS
—
Same quarter last year
Revenue
$2.02B
−2.9% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Not enough quarters on file yet.
Revenue by quarter
Dec 2024: $1.95BDec '24Mar 2025: $2.02BMar '25Jun 2025: $2.04BJun '25Sep 2025: $2.08BSep '25Dec 2025: $2.11BDec '25Mar 2026: $2.03BMar '26Jun 2026: $2.06BJun '26Sep 2026: $2.02BSep '26Latest $2.02B
StreetAlpha's call on ICLRStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ICLR
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ICLR

Technical Analysis

ICLR · as of the Nov 20 close · updated each morning
Moving sideways

The stock sits between its 20 and 50 day averages. It is 21% above its 200 day average, so the longer trend is still up. Momentum is weak (RSI 45). The nearest support is the Pivot S1 at $183.34, and the nearest resistance the Pivot at $187.15.

Short trendNeutral
Long trendBullish
MomentumWeak
StretchNormal
VolatilityNormal, 4.4%/day
Key levels
$219.0452 week high+17.3%
$199.6020 day average+6.9%
$190.56Swing high (Oct 22)+2.1%
$190.53Pivot R1+2.0%
$187.15Pivot+0.2%
$186.71Last close
$183.34Pivot S1−1.8%
$181.8350 day average−2.6%
$174.53100 day average−6.5%
$162.83Swing low (Jul 14)−12.8%
$147.31200 day average−21.1%
$66.5752 week low−64.3%
Indicators
RSI (14)44.58Middle of its rangeNeutral
MACD2.63Below its signal lineBearish
Stochastic15.4Near the bottom of its rangeOversold
ADX (14)30.3Trending down
Williams %R-89.1Oversold below −80, overbought above −20Oversold
CCI (20)-113.9Oversold below −100, overbought above 100Oversold
Rate of change−8.8%Change over 10 sessionsBearish
ATR (14)$8.13Typical daily range, 4.4% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Above
MA 200Above
What happened before, for ICLR

What happened before

See how ICLR did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ICLR usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ICLR has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ICLRHow many large options trades hit ICLR, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ICLR Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ●199 buying vs 193 selling
  • ▼Shares held by funds -4.8%
  • ●Funds holding -2
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holding
Q3 2026This quarterLast quarterChange
Funds holding424426−0.5%
In funds' top 101619−15.8%
Held by funds–––
New / increased45 / 15483 / 147−13.5%
Reduced / sold out149 / 44141 / 80−12.7%
Put/call ratio1.800.71+155.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ICLR institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ICLR Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$8.2M18 sales · 10 insiders
2026-08 sold $1.7M2026-09 sold $2.3M2026-10 sold $50K2026-11 sold $4.1MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 12Ciaran MurrayDirectorSale10,000$200.18$2.0M
Nov 2Ciaran MurrayDirectorSale3,452$205.66$710K
Nov 2Nigel Bernard John ClerkinCFOSale1,488$206.66$308K
Nov 2Emer LyonsChief Accounting OfficerSale264$206.66$55K
Nov 2Barry Edward BalfeCEOSale5,175$206.66$1.1M
Oct 23Emer LyonsChief Accounting OfficerSale272$182.37$50K
Every insider buy and sale for ICLR over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ICLR insider trades →

From SEC Form 4 filings by ICLR's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ICLR is in one of them and how their past ICLR trades turned out.

ICLR in the AI portfolios
Loading…

ICLR News Tone and Price

Loading…

ICLR News & Analysis

All StreetAlpha news →
ICLR in the news

ICLR Congress Trades

All congress trades →
Trades, 12 months
3
Buys
0
0%
Sells
3
100%
People
2
Last filed Sep 1
Who traded ICLR · since 2015
Latest 5 filings of 12
Kevin HernSell (partial)
$15K – $50KTraded Aug 14, 2026Filed Sep 1, 2026
$100K – $250KTraded Mar 5, 2026Filed Apr 3, 2026
$1K – $15KTraded Feb 12, 2026Filed Mar 12, 2026
$1K – $15KTraded Sep 4, 2024Filed Sep 6, 2024
$1K – $15KTraded Jun 12, 2024Filed Sep 2, 2024
PersonTypeAmountTradedFiledDelay
Kevin HernR · OKSell (partial)$15K – $50KAug 14, 2026Sep 1, 202618 d
Kevin HernR · OKSell$100K – $250KMar 5, 2026Apr 3, 202629 d
Julia LetlowR · LASell$1K – $15KFeb 12, 2026Mar 12, 202628 d
John JamesR · MISell$1K – $15KSep 4, 2024Sep 6, 20242 d
John JamesR · MIBuy$1K – $15KJun 12, 2024Sep 2, 202482 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Icon

ICON is an outsourced development and commercialization services provider based in Dublin, Ireland. It serves pharmaceutical, biotechnology, medical device, and government and public health organizations. Its services cover clinical development strategy, trial design, full study execution and commercialization of treatments. The company works across all phases of clinical development, from Phase I to Phase IV studies. Offerings also include clinical trial management, consulting, contract staffing, data solutions and laboratory services.

Headquarters
Dublin 18, Ireland